Please ensure Javascript is enabled for purposes of website accessibility

Quest Diagnostics Buys Blueprint Genetics to Help It Read Mountains of DNA Data

By Cory Renauer - Updated Jun 22, 2020 at 11:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With this acquisition, the medical testing giant gains a powerful tool that should help it turn data into healthcare progress.

Quest Diagnostics (DGX 2.64%) runs medical tests on one in three American adults each year, and there are treasure chests full of medical insights buried in the mountains of genetic data some of those tests generate. To help analyze and interpret all the sequenced genetic data that piles up, Quest recently acquired a privately held company called Blueprint Genetics for an undisclosed sum. 

All roads lead to Helsinki 

Quest Diagnostics is best known for processing the most commonly performed laboratory tests, but it has lots of capable competition in that niche, a condition that can quickly squeeze profit margins. So it's rapidly building a slate of next-generation DNA sequencing services to add to its menu of advanced diagnostic services; Blueprint will give it a greater capacity to interpret the results. 

Scientists looking at a model of a DNA double helix.

Image source: Getty Images.

In the seven years since its founding, Blueprint Genetics has grown  into a global leader in the genetic diagnostics business, with customers in more than 70 countries. It has a North American base of operations in Seattle, but Quest plans to allow it to continue operating independently from its headquarters in Helsinki, Finland.

New revenue streams

Thousands of diseases caused by genetic mutations affect an estimated 30 million Americans, and developing the first FDA-approved tests for one after another is a great way to stay a step ahead of the competition. 

The diagnostics business is extremely competitive, and depending too heavily on any single revenue stream isn't healthy. Quest Diagnostics is eager to build out its gene-based service offerings, and Blueprint's ability to interpret the data generated by genetic testing on a mass scale could expand its new owner's menu by leaps and bounds.   

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
$145.39 (2.64%) $3.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.